Literature DB >> 28425419

A Rare BSEP Mutation Associated with a Mild Form of Progressive Familial Intrahepatic Cholestasis Type 2.

Orith Waisbourd-Zinman1, Lea F Surrey2, Anna E Schwartz1, Pierre A Russo2, Jessica Wen1.   

Abstract

Progressive Familial Intrahepatic Cholestasis type 2 (PFIC2) is a rare cholestatic disorder diagnosed in infancy or childhood that can lead to severe hepatic fibrosis and liver failure. Mutations in the ABCB11 gene result in a deficiency of the bile salt export protein (BSEP) and accumulation of bile inside the hepatocytes. Hepatocellular carcinoma is another condition associated with severe forms of deletion mutations in the ABCB11 gene. Treatment options including ursodeoxycholic acid biliary diversion have mixed outcomes and some patients require liver transplantation. Here, we describe two siblings with an extremely mild form of PFIC2 inherited from heterozygous parents. The elder sibling had acute liver failure at the age of six months and both siblings had pruritus, cholestasis, coagulopathy and fat-soluble-vitamin deficiencies in infancy but have been asymptomatic past infancy. Genetic testing of the siblings revealed that each were compound heterozygotes for two missense mutations of the ABCB11 gene: p.C68Y and p.R832H. Medical treatment typical for PFIC2 has not been necessary for either patient. This is the first report of these variants following a mild course in two affected patients.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28425419     DOI: 10.5604/16652681.1235494

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  2 in total

1.  A Complex Case of Cholestasis in a Patient with ABCB4 and ABCB11 Mutations.

Authors:  Mariana Ferreira Cardoso; Joana Carvalho E Branco; Vera Anapaz; Catarina Graça Rodrigues; Rita Carvalho; David Horta; Alexandra Martins; Jorge Reis
Journal:  GE Port J Gastroenterol       Date:  2017-11-25

2.  Functional analysis of the correlation between ABCB11 gene mutation and primary intrahepatic stone.

Authors:  Lang Gan; Shuguang Pan; Jinchi Cui; Jie Bai; Peng Jiang; Yu He
Journal:  Mol Med Rep       Date:  2018-11-15       Impact factor: 2.952

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.